Skip to main navigation
Skip to content
Cincor Logo
Menu
  • Home
  • About
  • Baxdrostat
    • Hypertension
      • Causes of Hypertension
      • Treatment for Hypertension
    • Chronic Kidney Disease
      • Causes of CKD
      • Treatment for CKD
    • Primary Aldosteronism
      • Aldosterone Diagnosis
      • Aldosterone Renin Ratio
    • Publications and Posters
  • Pipeline
  • News Releases
  • Contact

Publications and Posters

November 7, 2022
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
Source
DOI: 10.1056/NEJMoa2213169
November 3, 2022
Results From a Phase 1 Study Demonstrating the Safety and Pharmacokinetics of the Aldosterone Synthase Inhibitor CIN 107 in Subjects With Varying Degrees of Renal Function 664.7 KB
Source
[American Society of Nephrology (ASN) Congress 2022. November 3, 2022. Freeman et al.]
October 18, 2022
Pharmacokinetics, pharmacodynamics, and safety results from a phase 1 multiple ascending dose study of the selective aldosterone synthase inhibitor CIN-107 (baxdrostat) 1.4 MB
Source
[International Society of Hypertension (ISH) Congress 2022. Freeman et. al, presented by James Hui, PhD]
August 28, 2022
Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of the aldosterone synthase inhibitor baxdrostat. 796.7 KB
Source
[European Society of Cardiology (ESC) Congress 2022. August 28, 2022. Freeman et al.]
  • Contact Us
  • Home
  • About
  • Baxdrostat
  • Pipeline
  • News Releases
  • Contact
Cincor Logo
© 2023 CinCor. All rights reserved
  • Privacy
  • LinkedIn
  • Twitter